Premas Biotech has received a grant from the Bill & Melinda Gates Foundation to advance the early-stage development of a thermostable circRNA-VLP rabies vaccine using its D-CRYPT Ver 3.0 platform. This initiative aims to deliver an affordable, durable, and easily deployable vaccine specifically for low- and middle-income countries (LMICs), where access to cold-chain infrastructure often limits vaccine distribution.
The circRNA platform represents a novel approach to vaccine development, designed to enhance both stability and efficacy in challenging global health settings. By leveraging this technology, Premas aims to accelerate the development of next-generation vaccines that can address critical unmet needs in LMICs.
Prabuddha Kundu, Co-Founder & Managing Director of Premas Biotech, said:
“This grant marks a significant milestone in advancing our circRNA-VLP vaccine platform. With the D-CRYPT™ Ver 3.0 technology, we are pushing the boundaries of what is possible in thermostable vaccine design. Our focus is to deliver innovative, next-generation solutions that address some of the most pressing global health challenges. At Premas, we remain deeply committed to redefining how vaccines are developed, stabilized, and deployed for maximum impact.”
Premas Biotech collaborates with global biopharmaceutical companies to develop technologies from gene discovery through IND (Investigational New Drug) development for both therapeutic and vaccine candidates. The company focuses on infectious diseases, cancer, metabolic disorders, and inflammation. Its core platforms — D-CRYPT, Axtex-4D, and C-Qwence — are specifically designed to address critical challenges in therapeutic innovation and development.